Allegations focus on two public offerings in August and September 2025 that allegedly raised approximately $76.7 million in net proceeds while GUTS shares traded at prices allegedly inflated by the Company’s interim Revita data.

NEW YORK, Aug. 27, 2026 /PRNewswire/ — SueWallSt alerts investors in Fractyl Health, Inc. (NASDAQ: GUTS) of a pending securities class action covering purchases between January 13, 2025 and January 29, 2026. Check if you might be eligible to recover your investment losses or contact Joseph E. Levi, Esq. at jlevi@SueWallSt.com or (888) SueWallSt.

GUTS shares fell a cumulative 74.86%, or $1.37 per share, from a January 28, 2026 close of $1.83 to $0.46 on January 30, 2026. The August 2025 offering produced approximately $20.7 million in net proceeds and the September 2025 offering approximately $56 million. The Court has set October 20, 2026 as the deadline to apply for lead plaintiff appointment.

The Alleged Offering-Window Concentration

The lawsuit asserts that both capital raises were announced on the same days as data releases the Company characterized in strongly favorable terms, including a September 26, 2025 announcement stating that Revita-treated patients “lost an additional 2.5% total body weight” after stopping GLP-1 drugs versus a 10% regain in sham-treated patients. As alleged, that pricing environment allowed the Company to sell 60 million shares at $1.00 per share.

Capital Markets Context in Clinical-Stage Financing

• Clinical-stage device and therapeutics issuers often time equity offerings around clinical readouts, particularly when favorable data can support higher share prices and financing valuations.
• The action claims investors purchasing into those windows relied on data the complaint contends was compromised by an outlier study site.
• Item 105 of Regulation S-K requires issuers to describe material factors making an investment or offering speculative or risky.
• The complaint charges that undisclosed site-level operational issues qualified as such a factor.
• Six-month Midpoint Cohort results reported January 29, 2026 showed 4.5% weight regain for Revita patients versus 7.5% in the sham arm.

Why Offering Timing Allegedly Matters to Investors

As alleged, management touted the Midpoint Cohort as an “important early randomized readout” while not disclosing that one of six sites had a relatively less robust diet and lifestyle counseling program. The action claims purchasers in and around the 2025 offerings paid prices that did not reflect that risk.

“Investors deserve transparency about material risks before a company taps the public markets for capital. The complaint here alleges that Fractyl Health raised roughly $76.7 million in back-to-back offerings on days that coincided with favorable interim Revita readouts, while operational problems at a study site allegedly went undisclosed.” — Joseph E. Levi, Esq.

Learn more about the case or call (888) SueWallSt.

WHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

Frequently Asked Questions About the GUTS Lawsuit

Q: Who is eligible to join the GUTS investor lawsuit? A: Investors who purchased GUTS stock or securities between January 13, 2025 and January 29, 2026 and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses — not on whether you still hold the shares.

Q: What specific misstatements does the GUTS lawsuit allege? A: The complaint alleges Fractyl Health, Inc. made materially false or misleading statements regarding the clinical efficacy of the Revita DMR System and the integrity of REMAIN-1 Midpoint Cohort results during the Class Period. When six-month data showing 4.5% weight regain and an “outlier site” with operational issues was disclosed, the stock price declined sharply.

Q: Who are the defendants named in the GUTS lawsuit? A: The complaint names Fractyl Health, Inc. and individual defendants including senior executives who signed SEC filings, made public statements, or certified financial disclosures under Sarbanes-Oxley.

Q: What do GUTS investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible as an absent class member.

Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the entire class. Lead plaintiffs are typically investors with the largest documented losses. Being appointed does not increase individual recovery but gives direct oversight of how the case is run.

Q: What if I already sold my GUTS shares — can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought during the Class Period and sold at a loss may still be eligible to participate.

Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in the securities class action, they are generally handled on a contingency basis, with any attorneys’ fees and expenses subject to court approval.

Q: What if I live outside the United States? A: U.S. securities class actions generally cover purchases on U.S. exchanges regardless of the investor’s country of residence.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@SueWallSt.com
Tel: (888) SueWallSt
Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

View original content to download multimedia:https://www.prnewswire.com/news-releases/suewallst-reminds-fractyl-health-inc-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-october-20-2026—guts-302861389.html

SOURCE SueWallSt.com